nach oben

The European Journal of Health Economics

Erschienen in:

02.06.2017 | Original Paper

The financial performance of the health care industry: a global, regional and industry specific empirical investigation

verfasst von: Gregor Dorfleitner, Felix Rößle

Erschienen in: The European Journal of Health Economics | Ausgabe 4/2018

Einloggen, um Zugang zu erhalten

Abstract

This article analyzes the financial (out-) performance of all listed health care companies. The health care sector outperformed the market in the period from 2000 to June 2015. The performance was driven by companies from Americas, and Asia as well as companies from the pharmaceuticals sub-segment. Additionally, bull periods appear to be the main driver for the outperformance. Euro-based investors can expect different outcomes of their investments to those of USD investors. However, the main trends remain unchanged.

For more details see http://www.eiu.com/industry/Healthcare.

Previous studies on health care used the SIC (Standard Industrial Classification) codes for their stock selection. As our analysis is global, we cannot use a code that is only available for US companies.

Andrea Frazzini’s data library is accessible via http://www.econ.yale.edu/~af227/data_library.htm.

We excluded the Australia sample as the number of companies is too low in order to obtain a trustworthy result.

DiMasi, J.A., Hansen, R.W., Grabowski, H.G.: The price of innovation: new estimates of drug development costs. J. Health Econ. 22, 151–185 (2003)CrossRefPubMed

Kola, I., Landis, J.: Can the pharmaceutical industry reduce attrition rates? Nat. Rev. Drug Discov. 3, 711–716 (2004)CrossRefPubMed

Adams, C.P., van Brantner, V.: Estimating the cost of new drug development: is it really $802 million? Health Aff. 25, 420–428 (2006)CrossRef

Adams, C.P., van Brantner, V.: Spending on new drug development. Health Econ. 19, 130–141 (2010)CrossRefPubMed

DiMasi, J.A., Grabowski, H.G., Hansen, R.W.: Innovation in the pharmaceutical industry: new estimates of R&D costs. J. Health Econ. 47, 20–33 (2016)CrossRefPubMed

Trsel, J., Payne, B., Karels, G.: Health care investing: is a higher dose of health care good for the portfolio? J. Invest. 23, 53–66 (2014)CrossRef

Bredthauer, J., Payne, B., Tresl, J., Karels, G.: Presidential parties, monetary regimes, and health care returns. Managerial Finance 41, 1059–1076 (2015)CrossRef

Fama, E.F., French, K.R.: Industry costs of equity. J. Finance Econ. 43, 153–193 (1997)CrossRef

Hong, H., Torous, W., Valkanov, R.: Do industries lead stock markets? J. Finance Econ. 83, 367–396 (2007)CrossRef

10.

Guirguis, H.S., Onochie, J., Rosen, H.: The post-offering performance of IPOs in the health care industry. J. Econ Finance 25, 194–205 (2001)CrossRef

11.

Dellva, W.L., DeMaskey, A.L., Smith, C.A.: Selectivity and market timing performance of fidelity sector mutual funds. Finance Rev. 36, 39–54 (2001)CrossRef

12.

Nofsinger, J., Varma, A.: Socially responsible funds and market crises. J. Bank. Finance 48, 180–193 (2014)CrossRef

13.

Aggarwal, R., Klapper, L., Wysocki, P.D.: Portfolio preferences of foreign institutional investors. J. Bank. Finance 29, 2919–2946 (2005)CrossRef

14.

Markowitz, H.: Portfolio selection. J. Finance 7, 77–91 (1952)

15.

Carhart, M.M.: On persistence in mutual fund performance. J. Finance 52, 57–82 (1997)CrossRef

16.

Sharpe, W.F.: Capital asset prices: a theory of market equilibrium under conditions of risk. J. Finance 19, 425–442 (1964)

17.

Lintner, J.: The valuation of risk assets and the selection of risky investments in stock portfolios and capital budgets. Rev. Econ. Stat. 47, 13–37 (1965)CrossRef

18.

Mossin, J.: Equilibrium in a capital asset market. Econometrica 34, 768–783 (1966)CrossRef

19.

Fama, E.F., French, K.R.: The cross-section of expected stock returns. J. Finance 47, 427–465 (1992)CrossRef

20.

Fama, E.F., French, K.R.: Common risk factors in the returns on stocks and bonds. J. Finance Econ. 33, 3–56 (1993)CrossRef

21.

Lesser, K., Rößle, F., Walkshäusl, C.: Socially responsible, green, and faith-based investment strategies: screening activity matters! Finance Res. Lett. 16, 171–178 (2016)CrossRef

22.

Newey, W.K., West, K.D.: A simple, positive semi-definite, heteroskedasticity and autocorrelationconsistent covariance matrix. Econometrica 55, 703–708 (1987)CrossRef

23.

Fama, E.F., French, K.R.: Size, value, and momentum in international stock returns. J. Finance Econ. 105, 457–472 (2012)CrossRef

24.

Griffin, J.M.: Are the Fama and French factors global or country specific? Rev. Financial Stud. 15, 783–803 (2002)CrossRef

25.

Black, F.: Beta and return. J. Portfolio Manag. 20, 8–18 (1993)CrossRef

26.

Luce, B.R., Mauskopf, J., Sloan, F.A., Ostermann, J., Paramore, L.C.: The Return on Investment in Health Care: from 1980 to 2000. Value Health 9, 146–156 (2006)CrossRefPubMed

27.

Pritchard, C., Wallace, M.S.: Comparing the USA, UK and 17 Western countries’ efficiency and effectiveness in reducing mortality. JRSM short reports 2, 60 (2011)CrossRefPubMedPubMedCentral

28.

Weinstein, M.C., Skinner, J.A.: Comparative effectiveness and health care spending—implications for reform. New Eng. J. Med. 362, 460–465 (2010)CrossRefPubMedPubMedCentral

29.

Grabowski, H., Vernon, J.: Returns to R&D on new drug introductions in the 1980s. J. Health Econ. 13, 383–406 (1994)CrossRefPubMed

30.

Pammolli, F., Magazzini, L., Riccaboni, M.: The productivity crisis in pharmaceutical R&D. Nat. Rev. Drug Discov. 10, 428–438 (2011)CrossRefPubMed

31.

DiMasi, J.A., Feldman, L., Seckler, A., Wilson, A.: Trends in risks associated with new drug development: success rates for investigational drugs. Clin. Pharmacol. Ther. 87, 272 (2010)CrossRefPubMed

32.

Grabowski, H., Vernon, J., DiMasi, J.A.: Returns on research and development for 1990s new drug introductions. Pharmacoeconomics 20, 11–29 (2002)CrossRefPubMed

33.

National Institute on Aging: Global health and aging. National Institute on Aging, National Institutes of Health, Washington (2011)

34.

Fricke, F.-U., Wähling, S., vd Schulenburg, J.-M.G.: The future Market for Pharmaceutical products in Germany. HEPAC Health Econ. Prev. Care, 28–34 (2000). doi:10.1007/s101980070021

35.

Kiencke, P., Daniel, D., Grimm, C., Rychlik, R.: Direct costs of Alzheimer’s disease in Germany. Eur. J. Health Econ. 12, 533–539 (2011)CrossRefPubMed

36.

Bickel, H.: Dementia in advanced age. Estimating incidence and health care costs. Zeitschrift fur Gerontologie und Geriatrie 34, 108–115 (2001)CrossRefPubMed

37.

Jokung, O., Macé, S.: Long-term health investment when people underestimate their adaptation to old age-related health problems. Eur. J. Health Econ. 14, 1003–1013 (2013)CrossRefPubMed

38.

Yashin, A.I., Arbeev, K.G., Arbeeva, L.S., Wu, D., Akushevich, I., Kovtun, M., Yashkin, A., Kulminski, A., Culminskaya, I., Stallard, E.: How the effects of aging and stresses of life are integrated in mortality rates. Insights for genetic studies of human health and longevity. Biogerontology 17, 89–107 (2016)CrossRefPubMed

39.

Bunker, J.P.: The role of medical care in contributing to health improvements within societies. Int. J. Epidemiol. 30, 1260–1263 (2001)CrossRefPubMed

40.

Diel, R., Rappenhöner, B.: The cost structure of illness due to hepatitis A in Germany. HEPAC Health Economics in Prevention and Care 1, 20–25 (2000)CrossRef

Titel: The financial performance of the health care industry: a global, regional and industry specific empirical investigation
verfasst von: Gregor Dorfleitner
Felix Rößle
Publikationsdatum: 02.06.2017
Verlag: Springer Berlin Heidelberg
Erschienen in: The European Journal of Health Economics / Ausgabe 4/2018
Print ISSN: 1618-7598
Elektronische ISSN: 1618-7601
DOI: https://doi.org/10.1007/s10198-017-0904-8

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2018

Cost-effectiveness of combined serum anti-Helicobacter pylori IgG antibody and serum pepsinogen concentrations for screening for gastric cancer risk in Japan

Costs associated with community acquired pneumonia in France

Autonomy and performance in the public sector: the experience of English NHS hospitals

Primary care supply and quality of care in England

Valuing EQ-5D-5L health states ‘in context’ using a discrete choice experiment

Introduction of therapeutic reference pricing in Slovenia and its economic consequences